Tullis, Elizabeth

Elexacaftor–Tezacaftor–Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele

Middleton, P. G., Mall, M. A., Dřevínek, P., Lands, L. C., McKone, E. F., Polineni, D., Ramsey, B. W., Taylor-Cousar, J. L., Tullis, E., Vermeulen, F., et al. (2019) · New England Journal of Medicine

Cystic Fibrosis Research AdvancesInhalation and Respiratory Drug Delivery

Cited by 2,198

A CFTR Potentiator in Patients with Cystic Fibrosis and the G551D Mutation

Ramsey, B. W., Davies, J., McElvaney, N. G., Tullis, E., Bell, S. C., Dřevínek, P., Griese, M., McKone, E. F., Wainwright, C. E., Konstan, M. W., et al. (2011) · New England Journal of Medicine

Cystic Fibrosis Research AdvancesInhalation and Respiratory Drug Delivery

Cited by 2,195

Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial

Heijerman, H. G. M., McKone, E. F., Downey, D. G., Van Braeckel, E., Rowe, S. M., Tullis, E., Mall, M. A., Welter, J. J., Ramsey, B. W., McKee, C. M., et al. (2019) · The Lancet

Cystic Fibrosis Research AdvancesPharmacogenetics and Drug Metabolism

Cited by 1,414

VX-445–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles

Keating, D., Marigowda, G., Burr, L., Daines, C., Mall, M. A., McKone, E. F., Ramsey, B. W., Rowe, S. M., Sass, L. A., Tullis, E., et al. (2018) · New England Journal of Medicine

Cystic Fibrosis Research AdvancesInhalation and Respiratory Drug Delivery

Cited by 726

Tezacaftor–Ivacaftor in Residual-Function Heterozygotes with Cystic Fibrosis

Rowe, S. M., Daines, C., Ringshausen, F. C., Kerem, E., Wilson, J., Tullis, E., Nair, N., Simard, C., Han, L., Ingenito, E. P., et al. (2017) · New England Journal of Medicine

Cystic Fibrosis Research AdvancesInhalation and Respiratory Drug Delivery

Cited by 522

VX-659–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles

Davies, J. C., Moskowitz, S. M., Brown, C., Horsley, A., Mall, M. A., McKone, E. F., Plant, B. J., Prais, D., Ramsey, B. W., Taylor-Cousar, J. L., et al. (2018) · New England Journal of Medicine

Cystic Fibrosis Research AdvancesInhalation and Respiratory Drug Delivery

Cited by 331

Exacerbation frequency and clinical outcomes in adult patients with cystic fibrosis

de Boer, K., Vandemheen, K. L., Tullis, E., Doucette, S., Fergusson, D., Freitag, A., Paterson, N., Jackson, M., Lougheed, M. D., Kumar, V., et al. (2011) · Thorax

Cystic Fibrosis Research AdvancesChronic Obstructive Pulmonary Disease (COPD) Research

Cited by 271

Effect of pulmonary exacerbations on long-term lung function decline in cystic fibrosis

Waters, V., Stanojevic, S., Atenafu, E. G., Lu, A., Yau, Y., Tullis, E., & Ratjen, F. (2012) · European Respiratory Journal

Cystic Fibrosis Research AdvancesChronic Obstructive Pulmonary Disease (COPD) Research

Cited by 256

Insulin Therapy to Improve BMI in Cystic Fibrosis–Related Diabetes Without Fasting Hyperglycemia

Moran, A., Pekow, P., Grover, P., Zorn, M., Slovis, B., Pilewski, J., Tullis, E., Liou, T. G., Allen, H., & the Cystic Fibrosis Related Diabetes Therapy Study Group (2009) · Diabetes Care

Cystic Fibrosis Research AdvancesDiabetes Treatment and Management

Cited by 240

Clinical development of triple-combination CFTR modulators for cystic fibrosis patients with one or two F508del alleles

Taylor-Cousar, J. L., Mall, M. A., Ramsey, B. W., McKone, E. F., Tullis, E., Marigowda, G., McKee, C. M., Waltz, D., Moskowitz, S. M., Savage, J., et al. (2019) · ERJ Open Research

Cystic Fibrosis Research AdvancesInhalation and Respiratory Drug Delivery

Cited by 105

Long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis and at least one F508del allele: 144-week interim results from a 192-week open-label extension study

Daines, C. L., Tullis, E., Costa, S., Linnemann, R. W., Mall, M. A., McKone, E. F., Polineni, D., Quon, B. S., Ringshausen, F. C., Rowe, S. M., et al. (2023) · European Respiratory Journal

Cystic Fibrosis Research AdvancesPharmacogenetics and Drug Metabolism

Cited by 100

Cystic fibrosis-related diabetes screening in adults: a gap analysis and evaluation of accuracy of glycated hemoglobin levels

Gilmour, J. A., Sykes, J., Etchells, E., & Tullis, E. (2019) · Canadian Journal of Diabetes

Cystic Fibrosis Research AdvancesDiabetes Management and Research

Cited by 51

Outcomes of patients with cystic fibrosis undergoing lung transplantation with and without cystic fibrosis-associated liver cirrhosis

Nash, E. F., Volling, C., Gutierrez, C. A., Tullis, E., Coonar, A., McRae, K., Keshavjee, S., Singer, L. G., Durie, P. R., & Chaparro, C. (2012) · Clinical Transplantation

Transplantation: Methods and OutcomesCystic Fibrosis Research Advances

Cited by 37

Pre-transplant factors associated with mortality after lung transplantation in cystic fibrosis: A systematic review and meta-analysis

Koutsokera, A., Varughese, R. A., Sykes, J., Orchanian-Cheff, A., Shah, P. S., Chaparro, C., Tullis, E., Singer, L. G., & Stephenson, A. L. (2019) · Journal of Cystic Fibrosis

Transplantation: Methods and OutcomesCystic Fibrosis Research Advances

Cited by 36